mHealth for Diabetes Adherence Support (mDAS)
Diabetes Mellitus, Type 2

About this trial
This is an interventional health services research trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus, Type 2, Medication Adherence, Telemedicine, Community Health Workers, Pharmacists, Mobile Health
Eligibility Criteria
Inclusion Criteria:
- Self-identified as Latino/Hispanic or African-American
- Verbal fluency in English or Spanish
- Latest A1c ≥ 8.0% (within 3 mo)
- History of Type 2 Diabetes (> 1 year)
- Between the ages of 21 and 75 years
- Unlimited mobile phone/text messaging plan with ability to reply to text messages
- Home environment capable of video conferencing with wireless signal
- Receives primary care at UI Health clinical site for at least one year, with one visit during past year
- Able and willing to provide informed consent (agree to data collection requirements, accept randomization, agree to home visitation with HC and pharmacist involvement, and participate for two years)
Exclusion Criteria:
- Unable to verbalize comprehension of study or impaired decision making
- Family/household member already participating in same study
- Currently receiving regular pharmacist support through Medication Therapy Management or equivalent
- History of, or planned, gastric bypass or transplant surgery
- History of bipolar or psychotic disorder
- Other severe comorbidities that require complex, aggressive, or palliative treatment, e.g., stage 4 or greater renal disease, liver failure, cancer (other than nonmelanoma skin cancer), terminal illness
- Investigator discretion for safety concerns
Sites / Locations
- University of Illinois Hospital and Health Sciences System
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Usual Care
mHealth for Diabetes Adherence Support
Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will change to the mDAS intervention arm for one year.
Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.